Literatur
-
1
Bollschweiler E. et al .
High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas.
Endoscopy.
2006;
38
149-156
-
2
Bollschweiler E. et al .
Staging of esophageal carcinoma: lenght of tumor and number of involved regional lymph nodes. Are these independent prognostic factors?.
J Surg Oncol.
2006;
94
355-363
-
3
Nagano H. et al .
Indications for gastrectomy after incomplete EMR for early gastric cancer.
Gastric Cancer.
2005;
8
149-154
-
4 Deutschland A.B.-b. K.i .Krebs in Deutschland, Häufigkeiten und Trends. Saarbrücken; Verlag 2000: 24-26
-
5
Neugut A I, Hayek M, Howe G.
Epidemiology of gastric cancer.
Semin Oncol.
1996;
23
281-291
-
6
Sawada T, Muto T.
Familial adenomatous polyposis: should patients undergo surveillance of the upper gastrointestinal tract?.
Endoscopy.
1995;
27
6-11
-
7
Park W S. et al .
Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer.
Cancer Res.
1999;
59
4257-4260
-
8
Messmann H, Schlottmann K.
Role of endoscopy in the staging of esophageal and gastric cancer.
Semin Surg Oncol.
2001;
20
78-81
-
9
Ziegler K. et al .
Comparison of computed tomography, endosonography, and intraoperative assessment in TN staging of gastric carcinoma.
Gut.
1993;
34
604-610
-
10
Siewert J R, Stein H J.
Classification of adenocarcinoma of the oesophagogastric junction.
Br J Surg.
1998;
85
1457-1459
-
11
Cuschieri A. et al .
Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group.
Br J Cancer.
1999;
79
1522-1530
-
12
Bonenkamp J J. et al .
Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients.
World J Surg.
1993;
17
410-414; discussion 415
-
13
Bottcher K. et al .
[Risk of surgical therapy of stomach cancer in Germany. Results of the German 1992 Stomach Cancer Study. German Stomach Cancer Study Group (‘92)].
Chirurg.
1994;
65
298-306
-
14
Falcone A.
Future strategies and adjuvant treatment of gastric cancer.
Ann Oncol.
2003;
14(Suppl 2)
ii45-47
-
15
Macdonald J S. et al .
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
N Engl J Med.
2001;
345
725-730
-
16
Lee J H, Han H S, Kim Y W. et al .
Laparoscopic wedge resection with handsewn closure for gastroduodenal tumors.
J Laparoendosc Adv Surg Tech A.
2003;
13
349-353
-
17
Tada M, Tanaka Y, Matsuo N. et al .
Mucosectomy for gastric cancer: current status in Japan.
J Gastroenterol Hepatol.
2000;
15(Suppl)
D98-102
-
18
Takeo Y. et al .
Endoscopic mucosal resection for early esophageal cancer and esophageal dysplasia.
Hepatogastroenterology.
2001;
48
453-457
-
19
Ono H.
Endoscopic submucosal dissection for early gastric cancer.
Chin J Dig Dis.
2005;
6
119-121
-
20
Kunisaki C. et al .
Appropriate lymph node dissection for early gastric cancer based on lymph node metastases.
Surgery.
2001;
129
153-157
-
21
Gotoda T. et al .
Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers.
Gastric Cancer.
2000;
3
219-225
-
22
Janunger K G, Hafstrom L, Nygren P. et al .
A systematic overview of chemotherapy effects in gastric cancer.
Acta Oncol.
2001;
40
309-326
-
23
Cunningham D. et al .
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
N Engl J Med.
2006;
355
11-20
-
24
Menges M. et al .
Low toxic neoadjuvant cisplatin, 5-fluorouracil and folinic acid in locally advanced gastric cancer yields high R-0 resection rate.
J Cancer Res Clin Oncol.
2003;
129
423-429
-
25
Ajani J A. et al .
Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.
J Clin Oncol.
2006;
24
3953-3958
-
26
Klautke G. et al .
Neoadjuvant radiochemotherapy in locally advanced gastric carcinoma.
Strahlenther Onkol.
2004;
180
695-700
-
27
Moehler M, Schimanski C C, Gockel I. et al .
(Neo)adjuvant strategies of advanced gastric carcinoma: time for a change?.
Dig Dis.
2004;
22
345-350
-
28
Hohler T, Mohler M.
[New chemotherapeutic options in advanced gastric cancer].
Onkologie.
2003;
26(Suppl 7)
54-59
-
29
Webb A. et al .
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
J Clin Oncol.
1997;
15
261-267
-
30
Ross P. et al .
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.
J Clin Oncol.
2002;
20
1996-2004
-
31
Vanhoefer U. et al .
Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
J Clin Oncol.
2000;
18
2648-2657
-
32
Gadgeel S M. et al .
Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer.
Am J Clin Oncol.
2003;
26
37-41
-
33
Van Cutsem E. et al .
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
J Clin Oncol.
2006;
24
4991-4997
-
34
Roth A D, Ajani J.
Docetaxel-based chemotherapy in the treatment of gastric cancer.
Ann Oncol.
2003;
14(Suppl 2)
ii41-44
-
35
Boku N. et al .
Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer.
J Clin Oncol.
1999;
17
319-323
-
36
Moehler M. et al .
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
Br J Cancer.
2005;
92
2122-2128
-
37
Bouche O. et al .
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study - FFCD 9803.
J Clin Oncol.
2004;
22
4319-4328
-
38
Al-Batran S E. et al .
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
J Clin Oncol.
2004;
22
658-663
-
39
Wagner A D, Grothe W, Haerting J. et al .
Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.
J Clin Oncol.
2006;
24
2903-2909; Review
PD Dr. Markus Möhler
Johannes-Gutenberg Universität Mainz
I. Medizinische Klinik und Poliklinik
Langenbeckstraße 1
55101 Mainz
Email: moehler@mail.uni-mainz.de
